Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk
SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the widely-used Tyrer-Cuzick model to predict five-year and remaining lifetime risk of breast cancer.
The study, “Association of Polygenic-based Breast Cancer Risk Prediction with Patient Management”, was first shared at the 2024 ASCO® Annual Meeting. Key findings include:
- RiskScore predicted a different risk level than Tyrer-Cuzick for nearly 20% of patients
- Patients with a ≥20% lifetime risk of breast cancer predicted by RiskScore were significantly more likely to have guidelines-aligned screening, such as mammography, breast MRI, and genetic counseling compared to those with